You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 信達生物(1801.HK)漲4% 達攸同®(貝伐珠單抗注射液)在印尼獲批
格隆匯 06-14 10:29
格隆匯6月14日丨信達生物(1801.HK)漲4%,報26.85元,總市值393.83億港元。公司昨日公吿稱,國家藥品監督管理局受理信達生物自主研發的託萊西單抗注射液的新藥上市申請。公司今早還發布公吿稱,達攸同®(貝伐珠單抗注射液,印尼商標:Bevagen®)獲得印度尼西亞食品藥品監督管理局批准用於治療轉移性結直腸癌,轉移性三陰性乳腺癌,晚期非小細胞肺癌,卵巢癌及宮頸癌五項適應症。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account